3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Stomach Neoplasms
12
Neoplasms
7
Carcinoma, Non-Small-Cell Lung
5
Ovarian Neoplasms
4
Triple Negative Breast Neoplasms
3
Neoplasm Metastasis
3
Sarcoma
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Advanced Solid Tumor
2
Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
1
Solid Tumor, Adult
1
Small Cell Lung Carcinoma
1
Recurrence
1
Pancreatic Neoplasms
1
PD-L1 Positive Non-small Cell Lung Cancer
1
NSCLC
1
Metastatic Castration Resistant Prostate Cancer
1
Malignant Neoplasms of Digestive Organs
1
Fallopian Tube Neoplasms
1
Cytochrome P450 Interaction
1
Carcinoma, Adenoid Cystic
1
Breast Neoplasms
1
Advanced Primary Liver Cancer
1
Advanced Cancer
1
Interventions
Nivolumab
19
Ipilimumab
9
linrodostat
6
relatlimab
4
Pemetrexed
4
Paclitaxel
4
Carboplatin
4
ARRY-334543
4
Docetaxel
3
regorafenib
2
anlotinib
2
abemaciclib
2
N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
2
Gemcitabine
2
Cyclophosphamide
2
Capecitabine
2
6-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline
2
vorolanib
1
trametinib
1
tislelizumab
1
sargramostim
1
ralimetinib
1
prexasertib
1
palifosfamide lysine
1
p38 Mitogen-Activated Protein Kinases
1
mirdametinib
1
lirilumab
1
indibulin
1
gedatolisib
1
fluzoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Advanced Cancer
×
apatinib
×
Clear all
NCT03243643
2017-09-08
HS:Hansoh;
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
Unknown
80 enrolled